TNF and metastatic prostate carcinoma: As expected, the FAS receptor signaling pathway appeared to be significantly affected in metastatic prostate cancer (Table 3) and during disease recurrence (Table 5), but neither the Fas receptor- nor the TNF-α signaling pathway were found to be significantly dysregulated in androgen-independent prostate cancer (Table 6).